IMPORTANT SAFETY INFORMATION

Keppra XR® extended-release tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Keppra XR® causes somnolence, dizziness, and behavioral abnormalities. The most common adverse reactions observed with Keppra XR® in combination with other AEDs were somnolence and irritability.

The adverse reactions that may be seen in patients receiving Keppra XR® are expected to be similar to those seen in patients receiving immediate-release Keppra® (levetiracetam) tablets.

Keppra® immediate-release tablets cause somnolence and fatigue, coordination difficulties, and behavioral abnormalities (e.g., psychotic symptoms, suicidal ideation, and other abnormalities), as well as hematological abnormalities. In adults experiencing partial onset seizures, the most common adverse reactions observed with Keppra® in combination with other AEDs were somnolence, asthenia, infection, and dizziness.

Keppra XR® should be gradually withdrawn to minimize the potential of increased seizure frequency.

Dosing must be individualized according to the patient’s renal function status. In patients with end stage renal disease on dialysis, it is recommended that immediate-release Keppra® be used instead of Keppra XR®. Please see Keppra.com for the Keppra® immediate-release tablets full prescribing information.

Please see Keppra XR® Medication Guide and Full Prescribing Information.

REFERENCES

1. Data on file. UCB, Inc.
2. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6:87-93.

*With this coupon, your patients pay the first $25 of their Keppra XR® or Keppra® co-pay and we pay the remaining out-of-pocket expense up to a maximum of $30. This coupon may not be reproduced and must accompany a valid, signed Keppra XR® prescription. No cash value. Offer not valid for prescriptions reimbursed or paid under any government health insurance program (e.g., Medicaid, Medicare) or any private payer in Massachusetts or where otherwise prohibited by law. Patients are responsible for reporting this rebate to any private insurer that covers any part of the prescription. Offer expires on 12/31/12. UCB may cancel or alter this program at any time without notice.